Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - BRAINSTORM CELL THERAPEUTICS INC. | bcli-20201231xex31d1.htm |
| EX-32.2 - EXHIBIT 32.2 - BRAINSTORM CELL THERAPEUTICS INC. | bcli-20201231xex32d2.htm |
| EX-32.1 - EXHIBIT 32.1 - BRAINSTORM CELL THERAPEUTICS INC. | bcli-20201231xex32d1.htm |
| EX-31.2 - EXHIBIT 31.2 - BRAINSTORM CELL THERAPEUTICS INC. | bcli-20201231xex31d2.htm |
| EX-21 - EXHIBIT 21 - BRAINSTORM CELL THERAPEUTICS INC. | bcli-20201231xex21.htm |
| EX-10.63 - EXHIBIT 10.63 - BRAINSTORM CELL THERAPEUTICS INC. | bcli-20201231xex10d63.htm |
| 10-K - 10-K - BRAINSTORM CELL THERAPEUTICS INC. | bcli-20201231x10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-201704, 333-201705, 333-225517, 333-225995 and 333-233349 on Form S-3 and Registration Statement Nos. 333- 333-131880, 333-168763, 333-175460, 333-182546, 333-198391, 333-213714 and 333-228981 on Form S-8 of our report dated February 4, 2021, relating to the financial statements of Brainstorm Cell Therapeutics Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2020
Brightman Almagor Zohar & Co.
Certified Public Accountants
A Firm in the Deloitte Global Network
Tel Aviv, Israel
February 4, 2021
